Jade Biosciences (JBIO) Stock: Buy, Sell, or Hold?
JBIO - Jade Biosciences, Inc. Common Stock
$14.59
-0.32 (-2.15%)
âŧ
5d:
+8.31%
30d:
-0.95%
90d:
-26.87%
WAIT
LOW Confidence
Analysis Updated: Oct 23, 2026 12:00 AM ET
Earnings: Nov 12, 2026
18d
Get Alerted When JBIO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: JBIO is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: JBIO is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: JBIO is currently trading at $14.59, which is considered fair relative to its 30-day fair value range of $13.51 to $15.95.
Technical Outlook: Technically, JBIO is in a downtrend. Immediate support is located at $12.85, while resistance sits at $15.44.
Market Sentiment: The stock scores a mixed 47/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. In the options market, Implied Volatility is low (8th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $50.12 (+243.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, JBIO is in a downtrend. Immediate support is located at $12.85, while resistance sits at $15.44.
Market Sentiment: The stock scores a mixed 47/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. In the options market, Implied Volatility is low (8th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $50.12 (+243.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$13.51 -
$15.95
Company Quality Score
45/100
(HOLD)
Options IV Signal
8th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
80.0%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 8th percentile)
- NEUTRAL: Mixed technical signals (47/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 243.6% below Wall St target ($50.12)
- WARNING: Composite score 45/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$13.51 -
$15.95
Current vs Trading Range
FAIR
Expected Move (7 Days)
Âą$2.05
(14.0%)
Support & Resistance Levels
Support Level
$12.85
Resistance Level
$15.44
Current Trend
Downtrend
Technical data as of
Oct 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-5.48
Wall Street Target
$50.13
(+243.6%)
Share & Embed Analysis
Last updated: October 24, 2026 5:04 AM ET
Data refreshes hourly during market hours. Next update: 6:04 AM
Data refreshes hourly during market hours. Next update: 6:04 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is JBIO showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
IONS
Ionis Pharmaceuticals Inc |
STRONG BUY
25 analysts |
$84 | 61 BUY |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
|
GPCR
Structure Therapeutics IâĻ |
STRONG BUY
16 analysts |
$106 | 50 HOLD |
|
APLS
Apellis Pharmaceuticals âĻ |
BUY
22 analysts |
$41 | 50 HOLD |
|
TSHA
Taysha Gene Therapies Inc |
STRONG BUY
13 analysts |
$13 | 58 HOLD |